Abstract
Background: Symptoms of psychosis is one of the common clinical manifestations of Alzheimer’s disease (AD). However, the pathophysiology behind psychosis is unknown.
Objective: The aim of the present study was to explore the relationship between Apolipoprotein E (APOE) genotype, Lewy body pathology, and psychosis in AD. Method: The data was obtained from the National Alzheimer’s disease Coordinating Centre (NACC), using the Uniform Data Set and the Neuropathology Data Set. Subjects with frequent neuritic plaque on CERAD, and Braak Stage of V or VI, corresponding to high probability of AD based on the NIA-AA Regan criteria were included in the analysis. Results: Subjects with two copies of ε4 alleles were significantly more likely to develop psychosis, both delusions and/or hallucinations, during the course of their illness. This association was gender-specific, only reaching significance in females. Our findings further showed that presence of two copies of ε4 allele was positively associated with the formation of Lewy bodies. Only in females with Lewy bodies was the effect of two copies of ε4 allele significant, reaching an odd ratio of 4.5. Conclusion: The APOE ε4 allele has a female-specific effect in inducing psychosis in AD through the formation of Lewy bodies.Keywords: Alzheimer's disease (AD), apolipoprotein E, neuropathology, lewy bodies, neuropsychiatric symptoms, delusions, hallucinations.
Current Alzheimer Research
Title:Gender and Pathology-Specific Effect of Apolipoprotein E Genotype on Psychosis in Alzheimer’s Disease
Volume: 14 Issue: 8
Author(s): Julia Kim, Corinne E. Fischer, Tom A. Schweizer and David G. Munoz*
Affiliation:
- Department of Laboratory Medicine, Room 2-097 CC Wing, St. Michael’s Hospital, 30 Bond Street. Toronto, Ontario, M5B 1W8,Canada
Keywords: Alzheimer's disease (AD), apolipoprotein E, neuropathology, lewy bodies, neuropsychiatric symptoms, delusions, hallucinations.
Abstract: Background: Symptoms of psychosis is one of the common clinical manifestations of Alzheimer’s disease (AD). However, the pathophysiology behind psychosis is unknown.
Objective: The aim of the present study was to explore the relationship between Apolipoprotein E (APOE) genotype, Lewy body pathology, and psychosis in AD. Method: The data was obtained from the National Alzheimer’s disease Coordinating Centre (NACC), using the Uniform Data Set and the Neuropathology Data Set. Subjects with frequent neuritic plaque on CERAD, and Braak Stage of V or VI, corresponding to high probability of AD based on the NIA-AA Regan criteria were included in the analysis. Results: Subjects with two copies of ε4 alleles were significantly more likely to develop psychosis, both delusions and/or hallucinations, during the course of their illness. This association was gender-specific, only reaching significance in females. Our findings further showed that presence of two copies of ε4 allele was positively associated with the formation of Lewy bodies. Only in females with Lewy bodies was the effect of two copies of ε4 allele significant, reaching an odd ratio of 4.5. Conclusion: The APOE ε4 allele has a female-specific effect in inducing psychosis in AD through the formation of Lewy bodies.Export Options
About this article
Cite this article as:
Kim Julia, Fischer E. Corinne, Schweizer A. Tom and Munoz G. David*, Gender and Pathology-Specific Effect of Apolipoprotein E Genotype on Psychosis in Alzheimer’s Disease, Current Alzheimer Research 2017; 14 (8) . https://dx.doi.org/10.2174/1567205014666170220150021
DOI https://dx.doi.org/10.2174/1567205014666170220150021 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Offer of Chemistry to Targeted Therapy in Cancer
Recent Patents on Biotechnology Gut Homing Molecule Regulation of the Pathogenesis and Treatment of Inflammatory Bowel Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Angiogenesis-Related Proteins - Their Role in the Pathogenesis and Treatment of Inflammatory Bowel Disease
Current Protein & Peptide Science Anti-HIV Drug Distribution to the Central Nervous System
Current Pharmaceutical Design Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Protein & Peptide Letters Anti-Angiogenic Approaches to Malignant Gliomas
Current Cancer Drug Targets The Blood Brain Barrier, Mechanisms of Cerebral Edema, and the Use of Anti-Inflammatory and other Anti-Edema Agents in Neuro-Oncology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS)
Current Reviews in Clinical and Experimental Pharmacology Neuropathological Correlates of Cerebral Multimorbidity
Current Alzheimer Research Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design An Update on Disease Modifying Antirheumatic Drugs
Inflammation & Allergy - Drug Targets (Discontinued) HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology The Biology of Persistent Infection: Inflammation and Demyelination Following Murine Coronavirus Infection of the Central Nervous System
Current Immunology Reviews (Discontinued) Opiate Drug Use and the Pathophysiology of NeuroAIDS
Current HIV Research Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews A Systematic Review of Drugs in Late-Stage Development for the Treatment of Multiple Sclerosis: A Focus on Oral Synthetic Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Currently Used Biologic Agents in the Management of Behcet’s Syndrome
Current Medicinal Chemistry